The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Exclusive Agreement Gives Precision Direct Commercial Access to MMA.INC's Global Combat Sports Ecosystem, Backed by Strategic Advisors Conor McGregor and Donald Trump Jr., Cofounder John Kavanagh and Board Director Laura Sanko Highlights Exclusive access to MMA.INC's global combat sports ecosystem1 of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countries MMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC 329 against Max Holloway on July 11, 2026 in his first UFC appearance in five years2) and Donald Trump Jr., cofounder John Kavanagh and board director and UFC commentator Laura Sanko 50/50 net revenue share in Year 1, transitioning to 75/25 in favor of Precision thereafter, with no upfront capital investment All Precision products are U.S. manufactured and third party tested, positioning the Company as a compliance first operator New high margin commercialization vertical into a large and engaged athletic community Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "Precision"), a publicly traded wellness company building a platform for high quality peptide formulations, today provides additional detail on its previously announced Exclusive Strategic Marketing Agreement (the "Agreement") with Mixed Martial Arts Group Limited ("MMA"), and outlines the strategic significance of the partnership for the Company's commercialization roadmap. A Differentiated Channel Into the Global Combat Sports Community Under the Agreement, Precision has secured exclusive marketing rights across MMA.INC's digitally connected combat sports ecosystem, which the Company believes represents a highly engaged, performance driven and recovery-focused consumer demographic.